EosGene Therapeutics
Safe and effective gene therapy solutions for patients with vision-threatening conditions, including retinal and rare genetic diseases.
At a glance
-
Development stage
Active / generating revenue
-
Investment stage
Pre-Seed
-
UNSW affiliation
Spinout - staff led
-
Technology readiness level
TRL-4
-
Female led
Yes
EosGene replaces lifelong eye injections for vision-threatening disease with a safe and affordable gene therapy solution.
Backed by AUD460K non-dilutive funding, global IP, and inclusion in the AUD238 million SMART CRC for regenerative medicine, EosGene targets a AUD67 billion market with precision and scalability.
-
EosGene’s NanoSyringe is a patented, light-triggered gene delivery platform. It enables a single IV infusion, activated only in target tissues to avoid repeat eye injections. The NanoSyringe is safer, scalable, and capable of carrying large genetic payloads, including CRISPR. Revenue will come from licensing, co-development deals, and eventual out-licensing of flagship assets, like EOS-103 for diabetic retinopathy and AMD.
-
- Patients with blinding conditions like AMD require monthly eye injections that are painful, expensive, and poorly tolerated.
- Gene therapies using viral vectors are risky, slow to produce, and cost millions per dose.
- The market needs scalable, affordable, and precise delivery solutions – especially for retinal and rare genetic diseases.
-
- Biopharma companies seeking safer, more efficient gene delivery, especially in ophthalmology, and rare diseases
- Cell/gene therapy manufacturers
-
- Patents granted in US, EU, UK, CA, AU
- >AUD500K non-dilutive funding
- SMART CRC partner (AUD238 million program)
- Validated in vivo with 13.4× HDR efficiency
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.